Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model

Journal of Antimicrobial Chemotherapy

Volumn 43, Issue 4, 1999, Pages 483-490

  Firsov, Alexander A ^a   Vasilov, Raif G ^a   Vostrov, Sergey N ^a   Kononenko, Olga V ^a   Lubenko, Irene Yu ^a   Zinner, Stephen H ^b  

^a Scientific and Technological Centre Lekbiotech   (Russian Federation)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; QUINOLONE DERIVATIVE; TROVAFLOXACIN;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; DRUG HALF LIFE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; KLEBSIELLA PNEUMONIAE; MATHEMATICAL ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 0032909076     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/43.4.483     Document Type: Article

References (22)

1. Firsov, A. A., Vostrov, S. N., Shevchenko, A. A. & Cornaglia, G. (1997). Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrobial Agents and Chemotheraphy 41, 1281-7.
2. Firsov, A. A., Vostrov, S. N., Shevchenko, A. A., Zinner, S. H. & Portnoy, Y. A. (1998). A new approach to in-vitro comparisons of antibiotics in dynamic models: equivalent AUC/MIC breakpoints and equi-efficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibility. Antimicrobial Agents and Chemotheraphy 42, 3481-7.
3. Graham, D. R., Klein, T., Torres, A., Niedermann, M. & the Trovan Nosocomial Pneumonia Study Group. (1997). A double blind, randomized, multicenter study of nosocomial pneumonia (NOS) comparing trovafloxacin with ciprofloxacin ± clindamycin/ metronidazole. In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 1997. Abstract LM-74, p. 378. American Society for Microbiology. Washington, DC.
4. Niederman, M., Traub, S., Ellison, W. T., Hopkins, D. W. & the Trovan Pneumonia Study Group. (1997). A double blind, randomized, multicenter, global study in hospitalized community acquired pneumonia (CAP) comparing trovafloxacin with ceftriaxone + erythromycin. In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 1997. Abstract LM-72, p. 377-8. American Society for Microbiology. Washington, DC.
5. Sullivan, J., Gezon, J., Williams Hopkins, D. & the Trovan Community Pneumonia Study Group. (1997). Double blind, randomized, multicenter study in ambulatory community acquired pneumonia (CAP) comparing trovafloxacin with clarithromycin. In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 1997. Abstract LM-73, p. 378. American Society for Microbiology. Washington, DC.
6. Adam, D. (1997). Comparative in-vitro activity of trovafloxacin against fresh bacterial isolates from pediatric patients. In Program and Abstracts of the Twentieth International Congress of Chemotherapy, Sydney, 1997. Abstract 2237, p. 27.
7. Bauernfeind, A. (1997). Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. Journal of Antimicrobial Chemotherapy 40, 639-51.
8. Felmingham, D., Robbins, M. J., Ingley, K., Mathias, I., Bhogal, H. A., Leakey, G. L. et al. (1997). In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. Journal of Antimicrobial Chemotherapy 39, Suppl. B, 43-9.
9. Kocagöz, S., Gür, D., Karademir, A., Akalin, He. & Ünal, S. (1997). Comparative in-vitro activity of trovafloxacin against 557 clinical isolates. In Abstracts of the First European Congress of Chemotherapy, Glasgow, 1997. Abstract F148. The Parthenon Publishing Group. New York.
10. Seifert, H. (1997). Comparative in-vitro activities of trovafloxacin, ciprofloxacin, ofloxacin, and fleroxacin against gram-negative blood isolates. Clinical Microbiology and Infection 3, Suppl. 2, Abstract P404, p. 91.
11. Takahata, M., Mitsuyama, J., Yamashiro, Y., Yonezawa, M., Araki, H., Yamada, H. et al. (1997). T-3811, a novel des-F(6)-quinolone: in-vitro and in vivo antimicrobial activities. In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 1997. Abstract F-159, p. 173. American Society for Microbiology, Washington, DC.
12. Visali, M., Jacobs, M. & Appelbaum, P. (1997). Activity of trovafloxacin compared to 7 other agents against 458 gram-negative non-fermenters. In Program and Abstracts of the Twentieth International Congress of Chemotherapy, Sydney, 1997. Abstract 2233, p. 26.
13. Seftone, A. M., Maskell, J. P., Rafay, A. M., Whiley, A. & Williams, J. D. (1997). The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria. Journal of Antimicrobial Chemotherapy 39, Suppl. B, 57-62.
14. Firsov, A. A., Shevchenko, A. A., Vostrov, S. N. & Zinner, S. H. (1998). Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrobial Agents and Chemotherapy 42, 659-65.
15. Madaras-Kelly, K. J., Ostergaard, B. E., Hovde, L B. & Rotschafer, J. C. (1996). Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrobial Agents and Chemotherapy 40, 627-32.
16. Teng, R., Harris, S. C., Nix, D. E., Schentag, J. J., Foulds, G. & Liston, T. E. (1995). Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. Journal of Antimicrobial Chemotherapy 36, 385-94.
17. Wise, R., Mortiboy, D., Child, J. & Andrews, J. M. (1996). Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). Antimicrobial Agents and Chemotherapy 40, 47-9.
18. Bergan, T. & Thorsteinsson, S. B. (1986). Pharmacokinetics and bioavailability of ciprofloxacin. In Proceedings of the First International Ciprofloxacin Workshop, Leverkusen, Germany, 1985. (Neu, H. C. & Weuta H., Eds), pp. 111-21. Excerpta Medica, Amsterdam.
19. Hoffken, G., Lode, H., Prinzing, C., Borner, K. & Koeppe, P. (1985). Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrobial Agents and Chemotherapy 27, 375-9.
20. Wise, R., Lister, D., McNulty, C. A. M., Griggs, D. & Andrews, J. M. (1986). The comparative pharmacokinetics of five quinolones. Journal of Antimicrobial Chemotherapy 18, Suppl. D, 71-81.
21. Schentag, J. J., Nix, D. E. & Forrest, A. (1993). Pharmacodynamics of the fluoroquinolones. In Quinolone Antimicrobial Agents, 2nd edn (Hooper, D. C. & Wolfson, J. S., Eds), pp. 259-71. American Society for Microbiology, Washington, DC.
22. Kang, S. L., Rybak, M. J., McGrath, B. J., Kaatz, G. W. & Seo, S. M. (1994). Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model. Antimicrobial Agents and Chemotherapy 38, 2702-9.